Related Experiment Video
Updated: Sep 11, 2025
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Clinical insight on the pathway of SLFN11 as emergent biomarker in SCLC
Daniela Scattolin1, Frank W J Heijboer2, Jules L Derks2
1Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.
Abstract:
Schlafen 11 (SLFN11) is a gene encoding for a protein involved in the irreversible arrest of cell replication under DNA-damaging stress. SLFN11 is expressed differently across various cancers. When overexpressed, SLFN11 inhibits tumor replication and growth by early recruitment to stressed replication forks, making tumors more sensitive to a range of anti-cancer treatments, including topoisomerase I-II inhibitors, DNA alkylating agents, platinum salts, anti-metabolites, anti-tumor antibiotics, poly ADP-ribose polymerase (PARP) inhibitors and immunotherapies. SLFN11 expression can be silenced in cancer cells through different epigenetic mechanisms, resulting in SLFN11 downregulation and resistance to anti-cancer treatments. In this context, SLFN11 is increasingly being recognized as a promising biomarker for predicting cancer treatment responses. Its expression levels can inform clinical decisions, helping to identify patients most likely to benefit from therapies that exploit replication stress and to select new drug combinations that specifically aim to overcome SLFN11 deficiency.
Insights
Schlafen 11 (SLFN11) protein inhibits cancer growth and enhances treatment sensitivity. SLFN11 downregulation via epigenetic silencing causes treatment resistance, highlighting its role as a predictive biomarker.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Schlafen 11 (SLFN11) encodes a protein crucial for cell cycle arrest under DNA-damaging stress.
- SLFN11 expression varies across cancer types and influences tumor response to therapy.
- Epigenetic silencing of SLFN11 leads to downregulation and acquired resistance to various anti-cancer treatments.
Purpose of the Study:
- To investigate the role of SLFN11 in cancer progression and treatment response.
- To explore SLFN11 as a potential biomarker for predicting therapeutic outcomes.
- To understand the mechanisms of SLFN11 silencing and its implications for cancer therapy.
Main Methods:
- Analysis of SLFN11 expression patterns in diverse cancer types.
- Investigation of SLFN11 function in cell replication under DNA-damaging conditions.
- Correlation of SLFN11 expression levels with patient response to multiple anti-cancer agents, including PARP inhibitors and immunotherapies.
Main Results:
- Overexpression of SLFN11 inhibits tumor replication and growth by recruiting to stressed replication forks.
- SLFN11 overexpression sensitizes tumors to a broad spectrum of anti-cancer treatments.
- Epigenetic silencing of SLFN11 confers resistance to DNA-damaging agents and other therapies.
Conclusions:
- SLFN11 is a key determinant of cancer cell sensitivity to DNA-damaging agents and other anti-cancer therapies.
- SLFN11 expression levels serve as a predictive biomarker for treatment response in various cancers.
- Targeting SLFN11 deficiency or leveraging SLFN11 expression can inform clinical decision-making and guide novel therapeutic strategies.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019